BWAY

BWAY

USD

BrainsWay Ltd. American Depositary Shares

$9.020+0.180 (2.036%)

Reaalajas hind

Healthcare
Meditsiiniseadmed
Iisrael

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$8.840

Kõrge

$9.280

Madal

$8.800

Maht

0.00M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

170.2M

Tööstusharu

Meditsiiniseadmed

Riik

Israel

Kauplemisstatistika

Keskmine maht

0.06M

Börs

NGM

Valuuta

USD

52 nädala vahemik

Madal $5.13Praegune $9.020Kõrge $11.79

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 1. mai 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

BWAY: BrainsWay Ltd. American Depositary Shares - What's Happening and What to Watch

Stock Symbol: BWAY Generate Date: 2025-05-01 12:27:31

Alright, let's break down what's been going on with BrainsWay, ticker symbol BWAY, and see what the data might be telling us. This company is in the medical device space, specifically working on noninvasive treatments for mental health conditions. They're a smaller player, with a market cap around $165 million and not a ton of shares trading hands daily, which is something to keep in mind – smaller stocks can sometimes jump around quite a bit.

Recent News Buzz

Looking at the news headlines we have here, there are a couple of key points. Back in mid-March, specifically March 12th, an analyst over at HC Wainwright & Co. put out a note reiterating their "Buy" rating on BrainsWay. Not only that, but they stuck with a pretty ambitious price target of $16. That's a significant vote of confidence from one firm, especially when you compare it to where the stock has been trading lately.

The other piece of news was from late February, just announcing when they'd report their financial results for the fourth quarter and full year of 2024. Earnings reports are always a big deal for companies, as they give investors a look under the hood at how the business is actually performing. While the news itself was just an announcement date, the actual results released around March 11th would have been the important part, and the stock's reaction tells a story.

So, the news picture is a bit mixed in terms of timing – we have a positive analyst view from March, but the earnings announcement preceded some price drops. The analyst target is definitely a positive signal, suggesting someone on Wall Street sees significant potential upside.

Checking the Price Action

Now, let's look at what the stock price has actually been doing over the last few months. If you glance at the chart data since early February, BWAY had a nice run-up, peaking around the $11.79 mark in mid-February. But things took a turn shortly after. Around the time of that earnings announcement news in late February, the price started to slide. This downtrend continued pretty consistently through March and April.

The stock finished April trading around $8.67. That's a fair bit lower than its February high and, crucially, way below that $16 analyst price target we just talked about. The trend has clearly been downwards recently, and the trading volume hasn't been particularly high on most days, which is typical for a smaller company like this. Lower volume can sometimes mean price moves, when they happen, can be more pronounced.

Putting It All Together: Outlook & Ideas

Okay, so we have a few pieces of the puzzle: a positive analyst target, a recent history of price decline, and AI predictions for the very near term.

What does this suggest? It's a bit of a mixed bag, honestly. The analyst's $16 target is a strong bullish signal, but the market hasn't been buying into it lately, given the clear downtrend since February. The AI model, looking just a couple of days out from today (May 1st), predicts a slight upward nudge – around 0% today, then roughly a 1.85% rise the next day, followed by another 2.07% the day after. This suggests the AI sees a potential for a small bounce from the current levels.

Given the recent price weakness, but also the positive analyst target and the AI's short-term upward prediction, the picture is complex. The strong downtrend is a major factor suggesting caution. However, the AI predicting a short-term rise from the current price area, combined with the stock being near a potential support level the AI noted ($8.74, and the last close was $8.67), might catch the eye of someone looking for a potential bounce play.

If you were considering this stock based on the AI's short-term optimism or the long-term analyst view despite the recent trend, a potential entry area could be around the current price levels, perhaps looking for it to hold near that $8.74 mark the AI mentioned as support.

For managing risk, the AI data suggests a potential stop-loss level around $7.76. This is a point where, if the stock falls below it, the recent downtrend might be accelerating, and cutting losses could be wise. On the flip side, if the AI's predicted bounce happens, a potential level to watch for taking some profits could be around $9.47, which is another level highlighted in the AI data.

Remember, these are just potential ideas based on the provided data points. The recent trend has been negative, which is a powerful force.

Company Context

Just a quick reminder about BrainsWay itself: they are focused on developing treatments using neurostimulation technology for mental health. This means their success is tied to clinical results, regulatory approvals, and adoption by doctors and hospitals. News related to their technology or financial performance is going to be particularly important for this stock. Being a small company with lower trading volume also means it can be more sensitive to news or larger buy/sell orders.

Putting it simply, there's a positive long-term target out there and the AI sees a tiny bit of upward movement coming soon, but the stock has been heading south for a while now. It's a situation with conflicting signals, leaning cautious due to the trend, but with potential catalysts if things turn around.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and investing involves risk. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Seotud uudised

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay with a Buy and maintains $16 price target.

Vaata rohkem
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target
GlobeNewswire

BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

BURLINGTON, Mass. and JERUSALEM, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments

Vaata rohkem
BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 3. mai 2025, 15:40

LangevNeutraalneTõusev

67.4% Kindlus

Risk ja kauplemine

Riskitase3/5
Keskmine risk
Sobib
Kasv
Kauplemisjuhend

Sisenemispunkt

$9.00

Võta kasum

$10.36

Peata kahjum

$8.12

Põhitegurid

PDI 32.3 on MDI 27.2 kohal ADX-iga 8.4, mis viitab tõusutrendile
Praegune hind on tugitasemele ($8.96) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 1.9x keskmisest (1,491), mis viitab suurenenud turuosalusele
MACD 0.0371 on signaalijoone 0.0344 kohal, mis viitab tõusvale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.